Use of tlr agonist in combination with immune checkpoint inhibitor and vegfr inhibitor in the preparation of drugs for treating tumors

Abstract

This application relates to the use of TLR agonists in combination with immune checkpoint inhibitors and VEGFR inhibitors in the preparation of drugs for treating tumors. Specifically, the TLR agonist involved in this application is a compound represented by formula (I) or its complex or a pharmaceutically acceptable salt thereof, and the immune checkpoint inhibitor is selected from PD‑1 inhibitors, PD‑L1 inhibitors or CTLA ‑4 inhibitor, the VEGFR inhibitor is apatinib or a pharmaceutically acceptable salt thereof.

Description

technical field [0001] The present application relates to the use of a TLR agonist in combination with an immune checkpoint inhibitor and a VEGFR inhibitor in the preparation of a medicament for treating tumors. Background technique [0002] Protein programmed death 1 (PD-1) is an inhibitory member of the CD28 receptor family, which also includes CD28, CTLA-4, ICOS and BTLA. PD-1 is expressed on activated B cells, T cells and myeloid cells. The original members of the family, CD28 and ICOS, were discovered based on the functional effect of adding monoclonal antibodies on enhancing T cell proliferation. PD-1 was discovered by screening for differential expression in apoptotic cells. Currently, Ono's Nivolumab and Merck's Pembrolizumab have been successfully approved for marketing for the treatment of unresectable or metastatic melanoma, non-small cell lung cancer, advanced renal cell carcinoma, Hodgkin's lymphoma, recurrent or metastatic disease Squamous cell carcinoma, et...

AI Technical Summary

Problems solved by technology

[0011] MEDIMMUNE has launched a clinical trial on the combination of TLR / 8 agonist MEDI9197 and durvalumab in the treatment of solid tumors or T-cell lymphoma, but there is no result yet (NCT02556463)

Images